Skip to main content

Amersham to Distribute InforMax Software in Latin America

SAN DIEGO, Oct. 26 – Amersham Biosciences has agreed to distribute InforMax’s desktop software in Latin America, the companies announced Friday.

In the exclusive distribution agreement, Piscataway, NJ-based Amersham will distribute InforMax’s Vector NTI Suite molecular biology software in Brazil, Argentina, Bolivia, Guyana, Colombia, Peru, Surinam, French Guiana, Chile, Nicaragua, Venezuela, Ecuador, Uruguay, Paraguay, Mexico, Panama, El Salvador, Honduras, Guatemala, Costa Rica, and all Caribbean countries except Cuba. 

Financial details of the agreement were not disclosed.

“Amersham Biosciences' leadership position in Latin America will be instrumental in expanding our customer base in those countries,” Alex Titomirov, CEO of Bethesda, Md.-based InforMax, said in a statement.

Last week, InforMax announced major changes in its leadership , including Titomirov, who is also chairman of InforMax’s board, stepping down from his CEO position upon the hiring of a replacement.

Amersham Biosciences, which last week was renamed from its former name Amersham Pharmacia Biotech , owns an equity stake in InforMax as part of a September 2000 collaboration deal integrating Amersham’s high throughput platforms with InforMax’s GenoMax software.

The Scan

Possibly as Transmissible

Officials in the UK say the B.1.617.2 variant of SARS-CoV-2 may be as transmitted as easily as the B.1.1.7 variant that was identified in the UK, New Scientist reports.

Gene Therapy for SCID 'Encouraging'

The Associated Press reports that a gene therapy appears to be effective in treating severe combined immunodeficiency syndrome.

To Watch the Variants

Scientists told US lawmakers that SARS-CoV-2 variants need to be better monitored, the New York Times reports.

Nature Papers Present Nautilus Genome, Tool to Analyze Single-Cell Data, More

In Nature this week: nautilus genome gives peek into its evolution, computational tool to analyze single-cell ATAC-seq data, and more.